Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Current and novel therapeutic opportunities for systemic therapy in biliary cancer | British Journal of Cancer
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Debio 1347 - an overview | ScienceDirect Topics
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors - ScienceDirect
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
Frontiers | Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
10-K
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial - The Lancet
10-K
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
